Project: BUPI – a long-acting lozenge with bupivacaine for pain relief of Oral Mucositis in cancer patients

Moberg Pharma and partners will further develop and commersialise BUPI - an innovative and superior long-acting treatment for cancer patients suffering from pain associated with Oral Mucositis (OM). BUPI will be evaluated in a phase III trial. The project will deliver a final product ready for registration and thereafter launch – with documented benefits for patients.

Acronym BUPI (Reference Number: 9794)
Duration 01/10/2015 - 01/10/2018
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 3

Project partner

Number Name Role Country
21772 Moberg Pharma AB Coordinator Sweden
21773 Oracain ApS Partner Denmark
21774 PCG Clinical Services AB Partner Sweden
21775 TFS Trial Form Support ApS Partner Denmark
21776 Department of Oncology Skåne University Hospital Lund Sweden Partner Sweden
21777 Aarhus University Hospital, Department of Oncology Partner Denmark
21778 Department of Oncology and Radiotherapy, University Hospital Herlev Partner Denmark